Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Q: Who received Neuronetics’ employee inducement awards?

Fourteen non-executive employees received restricted stock unit awards as employment inducements. The Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4), and the awards are subject to the company’s 2020 Inducement Incentive Plan.

Q: When do Neuronetics’ inducement restricted stock units vest?

Most awards vest in equal thirds on the first, second and third grant anniversaries. Allison Manzer’s separate 15,000-unit award and Erin DiMarco’s separate 12,000-unit award vest in equal thirds on the second, third and fourth anniversaries. Each installment requires continued employment through the applicable vesting date.

The equity awards include vesting schedules extending through the fourth anniversary of the grant date.

Rhea-AI Impact

(High)

Rhea-AI Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Rhea-AI Summary

Neuronetics (NASDAQ: STIM) granted restricted stock units to fourteen non-executive employees as inducements to their employment with the company. The Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4), subject to the company’s 2020 Inducement Incentive Plan.

The awards total 123,300 restricted stock units, calculated from the disclosed grants. Most vest in equal thirds on the first, second and third anniversaries of the grant date. Separate awards of 15,000 units to Allison Manzer and 12,000 units to Erin DiMarco vest in equal thirds on the second, third and fourth anniversaries. Manzer also received 29,250 units, while DiMarco also received 11,250 units, on the earlier schedule. Every installment requires continued employment through its applicable vesting date.

Positive

None.

Negative

Minor point. Forward-looking: it has not happened yet and may not happen.123,300 restricted stock units, calculated from disclosed grants, represent potential shareholder dilution as they vest.

Argus 15 min delay 63 alerts

-2.03% vs previous close $2.65 last price 8.5x rel. volume Open Argus

Details

Market Reaction – STIM

$2.10 – $3.05 Day Range

$201.92M Mkt Cap at Last Price

On Nov 4, the day this news came out, the latest delayed price for STIM is 2.03% below the previous close. Our momentum scanner has recorded 63 alerts for this stock so far that day. The latest delayed price is $2.65. Relative volume is exceptionally heavy at 8.5x what this stock usually trades by this time of day.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Key Figures

Award recipients: 14 employees RSU award: 29,250 RSUs RSU award: 15,000 RSUs +1 more

Award recipients: 14 employees; Non-executive employees receiving inducement awards
RSU award: 29,250 RSUs; Grant to Allison Manzer
RSU award: 15,000 RSUs; Additional grant to Allison Manzer; installments on the second, third, and fourth grant anniversaries
Vesting schedule: 1/3 on each of the first three anniversaries; Subject to continued service through each applicable vesting date

Key Terms

restricted stock units, nasdaq listing rule 5635(c)(4), transcranial magnetic stimulation, treatment-resistant depression

4 terms

restricted stock units financial

"Restricted stock units (“RSUs”)"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

nasdaq listing rule 5635(c)(4) regulatory

"In accordance with NASDAQ Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

transcranial magnetic stimulation medical

"provider of transcranial magnetic stimulation (TMS) treatment"

A noninvasive medical treatment that uses a changing magnetic field delivered through a coil placed near the head to stimulate specific areas of the brain, much like tapping a piano key to make a particular note play. Investors care because devices, clinical trial results, insurance coverage, and regulatory approvals determine commercial adoption and revenue potential for makers of the machines, clinics that offer the therapy, and related healthcare suppliers.

treatment-resistant depression medical

"indicated for the treatment of treatment-resistant depression (“TRD”) in adults"

A form of major depression that does not improve after a person has tried standard treatments such as common antidepressant medications and therapy; think of it as a stubborn problem that doesn’t respond to the usual fixes. It matters to investors because it represents a large unmet medical need and a higher-risk, higher-reward area for drug developers, with potential for premium pricing, regulatory scrutiny, and durable demand if an effective new therapy is approved.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

11/04/2026 - 04:30 PM EST

MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar^®TMS technology and direct patient care through the Greenbrook network of interventional psychiatry clinics, today announced the granting of inducement awards to fourteen non-executive employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to their respective employment with the Company. In all cases, vesting is subject to the recipient’s continued service with the Company through the applicable vesting date, and the awards are subject to the terms of the Company’s 2020 Inducement Incentive Plan.

Restricted stock units (“RSUs”)

Name	Number of Inducement Plan RSUs	Vesting Schedule
Chad McCatherin	9,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Nicholas Trabucco	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Maya McClain	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Alexandra Germain	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Jackie Fennelly	9,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Pia Arellano	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Ashley Reindel	9,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Egette Indelele	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Allison Manzer	29,250	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Allison Manzer	15,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Omar Saleh	9,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Alondra Pastrona	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Giana Berrios	2,400	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Michael Rosenfield	3,000	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Erin DiMarco	11,250	1/3 on first anniversary of grant date; 1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.
Erin DiMarco	12,000	1/3 on second anniversary of grant date; 1/3 on third anniversary of grant date; 1/3 on fourth anniversary of grant date, subject in each case to the recipient’s continued employment by the Company through the applicable vesting date.

About Neuronetics
Neuronetics, Inc. is a leader in interventional mental health, combining innovative treatment technologies with direct patient care. Through its NeuroStar^®Advanced Therapy system, the company is a leading provider of transcranial magnetic stimulation (TMS) treatment and, through Greenbrook, operates one of the largest interventional psychiatry clinic networks in the United States, offering both TMS and SPRAVATO^®therapies. NeuroStar Advanced Therapy is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication has not helped. NeuroStar Advanced Therapy is the leading TMS treatment for MDD in adults and is backed by what we believe is the largest clinical data set of any TMS treatment system for depression. Greenbrook treatment centers also offer SPRAVATO^®(esketamine) Nasal Spray, a prescription medicine indicated for the treatment of treatment-resistant depression (“TRD”) in adults as monotherapy or in conjunction with an oral antidepressant. It is also indicated for depressive symptoms in adults with MDD with acute suicidal ideation or behavior in conjunction with an oral antidepressant.¹

The NeuroStar Advanced Therapy System is cleared by the U.S. Food and Drug Administration for adults with MDD, as an adjunct for adults with obsessive-compulsive disorder, to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression), and as a first line adjunct for the treatment of MDD in adolescent patients aged 15-21. For safety information and indications for use, visit NeuroStar.com.

Neuronetics Contact:
Investors:
Mike Vallie or Mark Klausner
ICR Healthcare
443-213-0499
ir@neuronetics.com

Media:
EvolveMKD
646.517.4220
NeuroStar@evolvemkd.com

References
¹ The effectiveness of SPRAVATO^®in preventing suicide or in reducing suicidal ideation or behavior has not been demonstrated. Use of SPRAVATO^® does not preclude the need for hospitalization if clinically warranted, even if patients experience improvement after an initial dose of SPRAVATO^®. For more important safety information about SPRAVATO^®, please visit spravatohcp.com.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who received Neuronetics’ employee inducement awards?

Fourteen non-executive employees received restricted stock unit awards as employment inducements. The Compensation Committee approved the awards under Nasdaq Listing Rule 5635(c)(4), and the awards are subject to the company’s 2020 Inducement Incentive Plan.

When do Neuronetics’ inducement restricted stock units vest?

Most awards vest in equal thirds on the first, second and third grant anniversaries. Allison Manzer’s separate 15,000-unit award and Erin DiMarco’s separate 12,000-unit award vest in equal thirds on the second, third and fourth anniversaries. Each installment requires continued employment through the applicable vesting date.

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)